基于全基因组 DNA 甲基化特征预测贝伐珠单抗联合新辅助化疗治疗乳腺癌的病理完全缓解。
Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer.
机构信息
Department of Environmental and Occupational Health, College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Department of Biostatistics, Colleges of Medicine and of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
出版信息
PLoS One. 2020 Apr 16;15(4):e0230248. doi: 10.1371/journal.pone.0230248. eCollection 2020.
Abstract
ClinicalTrials.gov Identifier: NCT00203502.
摘要
ClinicalTrials.gov 标识符：NCT00203502。
Zotero 插件